These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 28454804)
21. Clinical Impact of the Cardio-Ankle Vascular Index for Predicting Cardiovascular Events After Acute Coronary Syndrome. Gohbara M; Iwahashi N; Sano Y; Akiyama E; Maejima N; Tsukahara K; Hibi K; Kosuge M; Ebina T; Umemura S; Kimura K Circ J; 2016 May; 80(6):1420-6. PubMed ID: 27116899 [TBL] [Abstract][Full Text] [Related]
22. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305 [TBL] [Abstract][Full Text] [Related]
23. Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. Kassem-Moussa H; Mahaffey KW; Graffagnino C; Tasissa G; Sila CA; Simes RJ; White HD; Califf RM; Bhapkar MV; Newby LK; Am Heart J; 2004 Sep; 148(3):439-46. PubMed ID: 15389230 [TBL] [Abstract][Full Text] [Related]
24. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. Saraf S; Christopoulos C; Salha IB; Stott DJ; Gorog DA J Am Coll Cardiol; 2010 May; 55(19):2107-15. PubMed ID: 20447533 [TBL] [Abstract][Full Text] [Related]
25. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191 [TBL] [Abstract][Full Text] [Related]
26. Prevalence of stroke/transient ischemic attack among patients with acute coronary syndromes in a real-world setting. Deitelzweig SB; Ogbonnaya A; Berenson K; Lamerato LE; Costas JP; Makenbaeva D; Corbelli J Hosp Pract (1995); 2010 Nov; 38(4):7-17. PubMed ID: 21068522 [TBL] [Abstract][Full Text] [Related]
27. Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes. Segev A; Strauss BH; Tan M; Buller CE; Mendelsohn AA; Langer A; Goodman SG; Int J Cardiol; 2008 Sep; 129(2):233-7. PubMed ID: 17976842 [TBL] [Abstract][Full Text] [Related]
28. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK; Tardif JC; Kittelson J JAMA Cardiol; 2018 Feb; 3(2):164-168. PubMed ID: 29071331 [TBL] [Abstract][Full Text] [Related]
29. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Boden WE; O'Rourke RA; Teo KK; Maron DJ; Hartigan PM; Sedlis SP; Dada M; Labedi M; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS; Am J Cardiol; 2009 Jul; 104(1):1-4. PubMed ID: 19576311 [TBL] [Abstract][Full Text] [Related]
30. Recurrent Stroke, Myocardial Infarction, and Major Vascular Events during the First Year after Acute Ischemic Stroke: The Multicenter Prospective Observational Study about Recurrence and Its Determinants after Acute Ischemic Stroke I. Kang K; Park TH; Kim N; Jang MU; Park SS; Park JM; Ko Y; Lee S; Lee KB; Lee J; Kim DE; Cho YJ; Kim JT; Kim DH; Cha JK; Han MK; Lee JS; Lee J; Oh MS; Choi JC; Lee BC; Hong KS; Bae HJ J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):656-64. PubMed ID: 26750575 [TBL] [Abstract][Full Text] [Related]
31. Predictors and Impact of In-Hospital Recurrent Myocardial Infarction in Patients With Acute Coronary Syndrome: Findings From Gulf RACE-2. Al Saleh AS; Alhabib KF; Alsheik-Ali AA; Sulaiman K; Alfaleh H; Alsaif S; Al Mahmeed W; Asaad N; Amin H; Al-Motarreb A; Al Suwaidi J; Hersi AS Angiology; 2017 Jul; 68(6):508-512. PubMed ID: 27784731 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249 [TBL] [Abstract][Full Text] [Related]
33. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621 [TBL] [Abstract][Full Text] [Related]
34. Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. Gaggin HK; Liu Y; Lyass A; van Kimmenade RR; Motiwala SR; Kelly NP; Mallick A; Gandhi PU; Ibrahim NE; Simon ML; Bhardwaj A; Belcher AM; Harisiades JE; Massaro JM; D'Agostino RB; Januzzi JL Circulation; 2017 Jan; 135(2):116-127. PubMed ID: 27881568 [TBL] [Abstract][Full Text] [Related]
35. A modified Essen stroke risk score for predicting recurrent cardiovascular events: development and validation. Sumi S; Origasa H; Houkin K; Terayama Y; Uchiyama S; Daida H; Shigematsu H; Goto S; Tanaka K; Miyamoto S; Minematsu K; Matsumoto M; Okada Y; Sato M; Suzuki N Int J Stroke; 2013 Jun; 8(4):251-7. PubMed ID: 22759563 [TBL] [Abstract][Full Text] [Related]
36. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM; J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227 [TBL] [Abstract][Full Text] [Related]
37. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). Krantz MJ; Kaul S J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777 [TBL] [Abstract][Full Text] [Related]
38. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014 [TBL] [Abstract][Full Text] [Related]
39. Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. Abtan J; Bhatt DL; Elbez Y; Sorbets E; Eagle K; Ikeda Y; Wu D; Hanson ME; Hannachi H; Singhal PK; Steg PG; Ducrocq G; Clin Cardiol; 2016 Nov; 39(11):670-677. PubMed ID: 27588731 [TBL] [Abstract][Full Text] [Related]
40. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB; Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]